Pursuant to Regulation 30 read with Schedule III to the SEBI Listing Regulations, Piramal Pharma has informed that the Nomination and Remuneration Committee of the Board of Directors of the Company at its meeting held on Friday, 26th July, 2024 approved grant of 4,830,836 stock options under the Plan 2022. The disclosure as required under Regulation 30 of SEBI Listing Regulations is enclosed as Annexure-1.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1618.50 |
| Dr. Reddys Lab | 1312.40 |
| Cipla | 1295.00 |
| Zydus Lifesciences | 930.00 |
| Lupin | 2285.05 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: